MAP3K2 Knockout Raji Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal population of Raji B lymphocytes engineered with a targeted disruption of the MAP3K2 gene. This loss-of-function model is designed for the study of MAP3K2-dependent signaling in B lineage cells without clonal selection artifacts.
Raji cells are an Epstein-Barr virus (EBV)-positive human Burkitt lymphoma B cell line originally derived from an 11-year-old male patient. These cells serve as a well-established model for B cell receptor (BCR) signaling, lymphomagenesis, and the study of EBV-associated B cell transformation.
MAP3K2 (MEKK2) is a serine/threonine kinase that functions as a MAP kinase kinase kinase, integrating signals from diverse stimuli. It is activated downstream of receptors and stress signals, with upstream regulators including TRAF2, TNF-alpha, IL-1, EGF, osmotic stress, and the Rho GTPases RAC1 and CDC42. Upon activation, MAP3K2 phosphorylates and activates downstream kinases such as MKK7 (MAP2K7) and MEK5 (MAP2K5), which in turn phosphorylate JNK (MAPK8/9) and ERK5 (MAPK7). These cascades regulate transcription factors including c-Jun and ATF2 through JNK, and MEF2C through ERK5, controlling gene expression linked to proliferation, survival, and stress responses. MAP3K2 also interacts with scaffold protein JIP1 and chaperone HSP70, modulating signaling specificity.
In the Raji B lymphocyte background, disruption of MAP3K2 offers a powerful tool to dissect the contribution of this kinase to BCR signaling and lymphomagenesis. MAP3K2 functions at a critical node linking B cell receptor activation and environmental stress to the JNK and ERK5 cascades. Knockout of MAP3K2 is expected to impair downstream phosphorylation of JNK and ERK5, attenuate AP-1 and NF-??B transcriptional activity, and alter cytokine production (e.g., IL-6, TNF-alpha). As a polyclonal knockout pool, this product reflects a spectrum of genetic editing events, providing a robust system to assess the overall functional impact of MAP3K2 loss without clonal bias, and is particularly suited for studying drug responses and adaptive signaling in B cell malignancies.
Typical research applications for these MAP3K2 knockout Raji polyclonal cells include the dissection of B cell receptor-mediated JNK and ERK5 signaling, validation of small-molecule inhibitors targeting the MAP3K pathway, and investigation of stress-induced apoptosis in lymphomas. Researchers can employ Western blot analysis of phospho-JNK and phospho-ERK5, RT-qPCR quantification of c-Jun and MEF2C mRNA levels, or flow cytometry-based Annexin V/PI apoptosis assays. Functional analyses using AP-1 and NF-??B luciferase reporters, BrdU proliferation assays, and multiplex cytokine profiling (IL-6, TNF-alpha) further enable quantitative profiling of MAP3K2-dependent cellular phenotypes. For technical inquiries and customization options, please contact Ascent Research.
